Table 1 Pathological and clinical data of the arrayed prostate cancers
No. of patients (%) | ||
|---|---|---|
Study cohort on TMAa | Biochemical relapse | |
Follow-up (month) | ||
N | 11,665 | 2769 (23.7%) |
Mean / median | 62.9 / 50.0 | – |
Age (y) | ||
≤ 50 | 334 | 81 (24.3%) |
51–59 | 3061 | 705 (23.0%) |
60–69 | 7188 | 1610 (22.4%) |
≥ 70 | 1761 | 370 (21.0%) |
Pretreatment PSA (ng/ml) | ||
< 4 | 1585 | 242 (15.3%) |
4–10 | 7480 | 1355 (18.1%) |
10–20 | 2412 | 737 (30.6%) |
> 20 | 812 | 397 (48.9%) |
pT stage (AJCC 2002) | ||
pT2 | 8187 | 1095 (13.4%) |
pT3a | 2660 | 817 (30.7%) |
pT3b-4 | 1528 | 847 (55.4%) |
Gleason grade | ||
≤ 3 + 3 | 2848 | 234 (8.2%) |
3 + 4 | 6679 | 1240 (18.6%) |
3 + 4 Tertiary 5 | 433 | 115 (26.6%) |
4 + 3 | 1210 | 576 (47.6%) |
4 + 3 Tertiary 5 | 646 | 317 (49.1%) |
≥ 4 + 4 | 596 | 348 (58.4%) |
pN stage | ||
pN0 | 6970 | 1636 (23.5%) |
pN+ | 693 | 393 (56.7%) |
Surgical margin | ||
Negative | 9990 | 1848 (18.5%) |
Positive | 2211 | 853 (38.6%) |